Isolated heart cells were prepared from animals newly born to
NaF-stimulated activity to basal activity increases from 6.3 at 2 days to 10.0 in the adult, a change which is not statistically significant.
We conclude that a cardiac receptor for glucagon is present early in neonatal period of the rat, but this receptor cannot effect activation of adenylate cyclase and an increase in heart rate, or depletion of glycogen. Even in the presence of lo-* GMP-PNP, the response to glucagon by cardiac adenylate cyclase depends on the age of the rat. In heart cells from a 7-day-old rat, thk response is barely measurable but the magnitude of the response increases each week.
Speculation
This study demonstrates that GMP-PNP, an analog of GTP, facilitates the activation of adenylate cyclase by glucagon in the neonatal rat heart. It remains to be determined whether GMP-PNP facilitates glucagon binding per se or the interaction of glucagon with adenylate clyclase. The effect of the naturally occurring GTP on newborn cardiac adenylate cyclase activity is unknown.
We have previously shown that glucagon does not stimulate adenylate cyclase activity in neonatal rat heart (5). Furthermore, when administered to the neonatal rat, glucagon neither depletes myocardial glycogen nor stimulates heart rate (5, 18) . Myocardial adenylate cyclase from adult rats is responsive to glucagon (5). Since guanine nucleotides have been reported to enhance the responsiveness of some adenylate cyclase systems to certain hoimones, including glucagon (i4), we have examined the effect of the GTP analog, 5'-GMP-PNP on the responsiveness to glucagon of the neonatal rat cardiac adenylate cyclase. We report here that the adenylate cyclase activity in heart cells isolated from 7-day-old rats is responsive to glucagon in the presence of M GMP-PNP.
METHODS AND MATERIALS
Pregnant rats were purchased to provide young rats of known age (19). Female adult and weanling rats were used; younger animals of either sex were used. 21 days of age as previously described (6). Cells were isolated from hearts of adult rats by the technique of Berry et al.
(1) using the reagents described in reference (6).
Adenylate cyclase activity was determined by the appearance of cyclic [32P]AMP according to the method of Pohl eP al. (13). The assay solution (50 p1 final volume) included 0.4 mM [ o -~~P I A T P , lo6 cpm/reaction; 8.1 mM MgCl,, 23.4 mM Tris-HC1, pH 7.6; 0.94 mM EDTA, 0.5 mM cyclic AMP, 11.1 mM phosphoenolpyruvate, and 4 pU/ml pyruvate kinase. The reaction was started by the addition of the heart cells which lyse immediately on addition to the hypotonic assay solution. (Lysis was assumed from the immediate uptake of trypan blue by cells exposed in preliminary experiments.) The reaction was incubated at 30' for 10 or 15 min and stopped by adding 50 pl of a recovery solution (40 mM ATP, 12.5 mM cyclic AMP, and 50,000 cpm cyclic [3H]AMP) and by heating for 3.5 min in a boiling water bath. Cyclic Protein was determined by the Biuret method (8) and adenylate cyclase activity was expressed as pmoles cyclic A M P formed per milligram of protein per minute of incubation.
The formation of cyclic A M P was linear for 10-15 min at 30" with heart cells from all ages studied. This linearity was maintained in the presence of M glucagon, M GMP-PNP and M glucagon, and M NaF. In the presence of these compounds the amount of cyclic A M P formed in 10 min was also linear with the amount of protein per assay tube over the range of 40-200 pg protein. The exception was in the presence of M N a F when the reaction was linear only to 70 pg protein. The time course showed a lag in cyclic AMP formation in the presence of M GMP-PNP alone. This lag time was not characterized for these studies. A substrate concentration of 0.4 mM ATP was chosen for all assays because preliminary experiments showed that higher concentrations of ATP in the assay with adult heart cells produced substrate inhibition.
Collagenase, type I, was purchased from Worthington Biochemical Corp. (20) . Hyaluronidase, type I, from bovine testes; pyruvate kinase, type 2 or 3; phosphoenolpyruvate, cyclic AMP, and ATP were purchased from Sigma Chemical Company (21) . ICN Pharmaceutical, Inc. (22) was the source of GMP-PNP and [~U -~~P I A T P , 10-16 Ci/mmol. Tritiated cyclic AMP was purchased from New England Nuclear (23). Glucagon was a gift of Dr. William Bromer (24) . All other chemicals were analytical grade.
RESULTS
The effect of increasing concentrations of GMP-PNP on the adenylate cyclase activity of adult rat heart cells is shown in Figure  1 . Stimulation of adenylate cyclase activity was seen at concentrations of GMP-PNP greater than M. With the addition of M glucagon, a much greater degree of activation was seen at even lower concentrations of GMP-PNP. Maximal effects of GMP-PNP were seen at M in the presence of 10-" glucagon, whereas in the absence of glucagon no plateau was seen at the concentrations of GMP-PNP studied.
The effect of increasing concentrations of glucagon alone on adenylate cyclase activity in heart cells from rats of different ages is shown in Figure 2 . Glucagon stimulated only the adenylate cyclase activity in heart cells from adult rats. However, when these studies were performed in the presence of M GMP-PNP, M glucagon, the points for the 14 and 21 day adult activities are significantly different than the control value. The act~vity from the 7-day heart at M is not significantly different than its control but the activity at glucagon is different ( P < 0.001). The value for the 2-day heart at glucagon is not significantly different than its control value. C A M P : cyclic AMP.
stimulation by M glucagon could be seen in heart cells from animals as young as 1 week (Fig. 3) . The degree of activation increased at both 14 days and 21 days. At 21 days, the activation was about half that seen in heart cells from adult animals.
The development of rat heart adenylate cyclase activity and its activation is summarized in Figure 4 . The basal adenylate cyclase activity of the rat heart increases with the age of the animals. By itself, M glucagon activates only adenylate cyclase from adult rats. In contrast, M glucagon in the presence of M GMP-PNP clearly activates adenylate cyclase activity in the 14-day-old rat heart, with some activation being evident in hearts of 7-day-old animals ( Fig. 3) . GMP-PNP, M, activates adenylate cyclase activity by itself at ages of 14 days and older, but to a far lesser degree than in combination with M glucagon. Activity elicited by NaF increases throughout the neonatal period. The ratio of NaF-stimulated activity to basal activity increases from 6.3 & S D 3.2 at 2 days to 10.0 & S D 2.8 for the adult, a change which is not statistically significant.
DISCUSSION
Kohrman (10) reported that rat heart adenylate cyclase activity falls and rises from the prenatal through adult period whether
basal norepinephrine stimulated or fluoride-stimulated activity is measured (10). Our results agree more with those of Brus (3) and Brus and Hess (4) which show a 2-fold increase in cardiac adenylate cyclase activities during the neonatal to adult period. We see a 3-to Cfold increase in basal and fluoride-stimulated cardiac adenylate cyclase activity during development. The greater increase may reflect the use of isolated cells rather than washed particles if it is assumed that washed particles are a more "damaged" membrane system than are the isolated cells.
The adult rat heart responds to either epinephrine or glucagon with positive chronotropic and inotropic effects and an increase in percentage of total phosphorylase activity which is in the active or "a" form (9, 12, 17). The mechanism by which epinephrine and glucagon appear to act is the activation of membrane-bound adenylate cyclase and a consequent increase in intracellular concentration of cyclic AMP. In the neonatal rat, glucagon activates adenylate cyclase and depletes glycogen in the liver but not in the heart, although epinephrine is active in both neonatal tissues (18) . We have suggested previously that the glucagon receptor for the adenylate cyclase system either has not developed or is inoperative in the neonatal rat heart, whereas the epinephrine receptor is already functional (5). We find in the present studies that glucagon can activate cardiac adenylate cyclase in the presence of the GTP analog, GMP-PNP, as early as 7 days after birth. We conclude that a receptor for glucagon is present in neonatal rat heart but this receptor cannot effect activation of adenylate cyclase, an increase in heart rate, or depletion of glycogen. Moreover, even in the presence of M GMP-PNP, the magnitude of response to glucagon by cardiac adenylate cyclase depends on the age of the rat. In heart cells from a 7-day-old rat the response is barely measurable but the degree of the response increases each week (Fig. 3) .
Guanine nucleotides can regulate activity in many adenylate cyclase systems (2). Since GTP and GDP have opposing effects on
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C .* some adenylate cyclase systems, and since GTP is readily hydrolyzed to GDP, GMP-PNP, which is resistant to hydrolysis at its terminal phosphate, has been used as a GTP analog (16) . GMP-PNP differs from GTP in that GMP-PNP has proven to be a more potent activator of many adenylate cyclase systems than GTP (11) and, unlike GTP, to be an irreversible activator (7). Activation is seen in the absence of hormones but activation is cooperative with hormones. From detailed kinetic analyses of fat cell and liver plasma membranes, Rodbell (14) has proposed that the binding of GMP-PNP causes the enzyme to exist in a state that has a higher substrate turnover (V,), but is highly susceptible to inhibition by protonated ATP. Binding of both hormone and GMP-PNP causes the enzyme to exist in a state that has the higher substrate turnover (V,), but which is no longer susceptible to inhibition by protonated ATP. Cuatrecasas et al. (7) have suggested that both GMP-PNP and GTP pyrophosphorylate the enzyme but that the enzyme-PNP is stable whereas the enzymepyrophosphate is rapidly hydrolyzed stepwise (7). They also demonstrated a lag time for GMP-PNP activation of adenylate cyclase.
The results reported here are consistent with a role of GMP-P N P which facilitates the action of glucagon either by inducing a receptor site for glucagon so that glucagon may bind and act or by stabilizing an enzyme conformation with which glucagon can now effectively interact. Since the effect of GMP-PNP on the binding of glucagon to liver plasma membranes is to decrease the amount of glucagon bound (12), we favor the hypothesis that GMP-PNP induces a structural change in a protein or in adenylate cyclase such that adenylate cyclase is activated when glucagon is bound to its receptor. :, 20 --3. Brus, R.: Adenylate cyclase activity in developing rat heart. Pol. J. Pharmacol. 
Extract
Twenty-four jaundiced neonates were studied, 12 in the treatment group and 12 in the untreated group. Patients were randomly selected to receive oral riboflavin. The mean 24-hr bilirubin decrease was determined during phototherapy. Blue light (420-470 nn) energy ranged fran 6-10 pW/cmZ. The observed 24-hr bilirubin decrease was compared with the expected decrease based on an energy-dose-response relationship. Riboflavin-treated infants received either 6-7 pW/cm2 blue light energy or 8-10 pW/cm2 (same as control group). Those infants receiving less energy than the control group (8-10 pW/cm2) had a mean 24-hr bilirubin decrease (3.05 mg/100 m1/24 hr) equal to the control group (3.09 mg/100 m1/24 hr). Those riboflavin-treated infants receiving energy equal to the control group showed a greater decline (5.2 mg/100 m1/24 hr) in their mean 24-hr bilirubin. Although effective, additional in vivo studies are required to clarify the full effects, especially on DNA, of using photosensitizers such as riboflavin in the presence of bilirubin and blue light energy (420-470 nm).
Speculation
Riboflavin may becane an inportant adjunct to phototherapy for neonatal hyperbilirubinemia. As a producer of singlet oxygen it is capable of transferring enough energy to overcane the oxygen quenching effect of bilirubin in its rapid degradation.
Riboflavin (6',7-dimethyl-9-(D-If-ribityl) isoalloxazine is an essential dietary constituent for mammals (9). The mono-or dinucleotide form functions as the prosthetic group of a number of important enzymes. Flavin mononucleotide, riboflavin 5'-phosphate is formed from riboflavin and ATP catalyzed by flavokinase. Further addition of ATP with the mononucleotide forms PP, and FAD, an important nucleotide and coenzyme in cellular respiration. All biologic functions of riboflavin appear to be limited to its contribution to the synthesis of these two coenzymes. In man, ingested riboflavin is excreted largely unchanged or as riboflavin 5'-phosphate (FMN).
Recent in vitro (7) and in vivo (4) evidence indicates that riboflavin enhances the photodecomposition of bilirubin. Application of this principle to phototherapy for neonatal hyperbilirubinemia using blue light energy in a predictable doseresponse relationship (5) forms the basis for this report.
MATERIALS AND METHODS
All infants studied were at term (38-40 weeks) and predominantly Caucasian. Assignment to the study was made only after the infants were committed to phototherapy for hyperbilirubinemia by their private pediatricians (10).
Study subjects included 24 infants born at St. Francis Hospital, Tulsa, Oklahoma. There were 12 males and 12 females. Hyperbilirubinemia was defined as a serum bilirubin concentration greater than 9 mg/100 ml and phototherapy was initiated at or above this level (range 9-18 mg/100 ml). Blue light energy was administered and measured as described in a previous report (5).
Serum bilirubin was collected and measured. All infants studied had developmental (physiologic) jaundice with no laboratory or clinical evidence of illness or hemolytic process. A system of random numerical selection was used to determine which patients
